Abstract
To examine the impact of glutamate on post-operative seizures and survival in a cohort of patients with grade II to IV supratentorial glioma. A retrospective analysis was performed on 216 patients who underwent surgery for supratentorial gliomas. Primary explanatory variables were peritumoural and/or tumoural glutamate concentrations, glutamate transporter expression (EAAT2 and SXC). Univariate and multivariate survival analysis was performed with primary outcomes of time to first post-operative seizure and overall survival. Subgroup analysis was performed in patients with de novo glioblastomas who received adjuvant chemoradiotherapy. 47 (21.8 %), 34 (15.8 %) and 135 (62.5 %) WHO grade II, III and IV gliomas respectively were followed for a median of 15.8 months. Following multivariate analysis, there was a non-significant association between higher peritumoural glutamate concentrations and time to first post-operative seizure (HR 2.07, CI 0.98–4.37, p = 0.06). In subgroup analysis of 81 glioblastoma patients who received adjunct chemoradiotherapy, peritumoural glutamate concentration was significantly associated with time to first post-operative seizure (HR 3.10, CI 1.20–7.97, p = 0.02). In both the overall cohort and subgroup analysis no glutamate cycle biomarkers were predictive of overall survival. Increased concentrations of peritumoural glutamate were significantly associated with shorter periods of post-operative seizure freedom in patients with de novo glioblastomas treated with adjuvant chemoradiotherapy. No glutamate cycle biomarkers were predictive of overall survival. These results suggest that therapies targeting glutamate may be beneficial in tumour associated epilepsy.
Similar content being viewed by others
References
Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neurooncology 15(7):961–967. doi:10.1093/neuonc/not057
Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Parraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G (2014) Epileptic seizures in diffuse low-grade gliomas in adults. Brain J Neuro 137(Pt 2):449–462. doi:10.1093/brain/awt345
Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A (2009) Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 111(2):282–292. doi:10.3171/2009.2.JNS081132
You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, Sang L, Wang Z, Li GL, Li SW, Song YJ, Kang CS, Jiang T (2012) Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neurooncology 14(2):230–241. doi:10.1093/neuonc/nor205
Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenite DG, Aaronson NK, Taphoorn MJ, Baaijen H, Vandertop WP, Muller M, Postma TJ, Heimans JJ (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54(4):514–520. doi:10.1002/ana.10712
Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, Sontheimer H (2011) Glutamate release by primary brain tumors induces epileptic activity. Nat Med 17(10):1269–1274. doi:10.1038/nm.2453
Campbell SL, Buckingham SC, Sontheimer H (2012) Human glioma cells induce hyperexcitability in cortical networks. Epilepsia 53(8):1360–1370. doi:10.1111/j.1528-1167.2012.03557.x
Yuen TI, Morokoff AP, Bjorksten A, D’Abaco G, Paradiso L, Finch S, Wong D, Reid CA, Powell KL, Drummond KJ, Rosenthal MA, Kaye AH, O’Brien TJ (2012) Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology 79(9):883–889. doi:10.1212/WNL.0b013e318266fa89
Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, Warren PP, White DM, Reid MA, Eschbacher JM, Berens ME, Lahti AC, Nabors LB, Sontheimer H (2015) SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med 7(289):289ra286. doi:10.1126/scitranslmed.aaa8103
Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65(1):1–105
Ye ZC, Rothstein JD, Sontheimer H (1999) Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19(24):10767–10777
Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, Eyupoglu IY (2008) Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 14(6):629–632. doi:10.1038/nm1772
Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H (2007) Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67(19):9463–9471. doi:10.1158/0008-5472.CAN-07-2034
Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59(17):4383–4391
Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7(9):1010–1015. doi:10.1038/nm0901-1010
Ramaswamy P, Aditi Devi N, Hurmath Fathima K, Dalavaikodihalli Nanjaiah N (2014) Activation of NMDA receptor of glutamate influences MMP-2 activity and proliferation of glioma cells. Neurol Sci 35(6):823–829. doi:10.1007/s10072-013-1604-5
de Groot JF, Liu TJ, Fuller G, Yung WK (2005) The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65(5):1934–1940. doi:10.1158/0008-5472.CAN-04-3626
Merriel RB, Gibbs P, O’Brien TJ, Hibbert M (2011) BioGrid Australia facilitates collaborative medical and bioinformatics research across hospitals and medical research institutes by linking data from diverse disease and data types. Hum Mutat 32(5):517–525. doi:10.1002/humu.21437
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55(4):475–482. doi:10.1111/epi.12550
Clarke G, O’Mahony S, Malone G, Dinan TG (2007) An isocratic high performance liquid chromatography method for the determination of GABA and glutamate in discrete regions of the rodent brain. J Neurosci Methods 160(2):223–230. doi:10.1016/j.jneumeth.2006.09.006
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, The National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (10):987–996. doi:10.1056/NEJMoa043330
Roslin M, Henriksson R, Bergstrom P, Ungerstedt U, Bergenheim AT (2003) Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 61(2):151–160
Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J (2000) Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol 47(1):11–22
Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ (2010) In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 97(1):11–23. doi:10.1007/s11060-009-9990-5
Kohling R, Senner V, Paulus W, Speckmann EJ (2006) Epileptiform activity preferentially arises outside tumor invasion zone in glioma xenotransplants. Neurobiol Dis 22(1):64–75. doi:10.1016/j.nbd.2005.10.001
Stephens ML, Williamson A, Deel ME, Bensalem-Owen M, Davis VA, Slevin J, Pomerleau F, Huettl P, Gerhardt GA (2014) Tonic glutamate in CA1 of aging rats correlates with phasic glutamate dysregulation during seizure. Epilepsia 55(11):1817–1825. doi:10.1111/epi.12797
During MJ, Spencer DD (1993) Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341(8861):1607–1610
Gao X, Wang H, Cai S, Saadatzadeh MR, Hanenberg H, Pollok KE, Cohen-Gadol AA, Chen J (2014) Phosphorylation of NMDA 2B at S1303 in human glioma peritumoral tissue: implications for glioma epileptogenesis. Neurosurg Focus 37(6):E17. doi:10.3171/2014.9.FOCUS14485
Liubinas SV, D’Abaco GM, Moffat BM, Gonzales M, Feleppa F, Nowell CJ, Gorelik A, Drummond KJ, O’Brien TJ, Kaye AH, Morokoff AP (2014) IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas. Epilepsia. doi:10.1111/epi.12662
Pallud J, Le Van Quyen M, Bielle F, Pellegrino C, Varlet P, Labussiere M, Cresto N, Dieme MJ, Baulac M, Duyckaerts C, Kourdougli N, Chazal G, Devaux B, Rivera C, Miles R, Capelle L, Huberfeld G (2014) Cortical GABAergic excitation contributes to epileptic activities around human glioma. Sci Transl Med 6(244):244ra89. doi:10.1126/scitranslmed.3008065
Campbell SL, Robel S, Cuddapah VA, Robert S, Buckingham SC, Kahle KT, Sontheimer H (2015) GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy. Glia 63(1):23–36. doi:10.1002/glia.22730
van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB, EORTC Radiotherapy and Brain Tumor Groups, The UKMRC (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366 (9490):985–990. doi:10.1016/S0140-6736(05)67070-5
Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ (2014) Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2014-308136
Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ (2016) Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. J Neuro Oncol 126(2):347–354. doi:10.1007/s11060-015-1975-y
Robert SM, Ogunrinu-Babarinde T, Holt KT, Sontheimer H (2014) Role of glutamate transporters in redox homeostasis of the brain. Neuro Chem Int. doi:10.1016/j.neuint.2014.01.001
Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M, Bours V (2009) Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 9:372. doi:10.1186/1471-2407-9-372
Takeuchi S, Wada K, Nagatani K, Otani N, Osada H, Nawashiro H (2014) Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma. Neurol India 62(1):42–47. doi:10.4103/0028-3886.128280
Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine HA (2009) Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 27(25):4155–4161. doi:10.1200/JCO.2008.21.6895
Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA (2010) Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 116(7):1776–1782. doi:10.1002/cncr.24957
Liubinas SV, Drummond KJ, Desmond PM, Bjorksten A, Morokoff AP, Kaye AH, O’Brien TJ, Moffat BA (2014) Glutamate quantification in patients with supratentorial gliomas using chemical shift imaging. NMR Biomed 27(5):570–577. doi:10.1002/nbm.3095
Acknowledgments
Dr. Andrew Neal conducted statistical analysis with the assistance of Mark Tacey from Centre for Clinical Epidemiology, Biostatistics and Health Services Research, Royal Melbourne Hospital, University of Melbourne, VIC 3050.
Funding
Dr. Andrew Neal was supported by an Australian Postgraduate Award Scholarship (University of Melbourne), The UCB Pharma Clinical Scholarship and by the Royal Melbourne Hospital Neuroscience Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Neal, A., Yuen, T., Bjorksten, A.R. et al. Peritumoural glutamate correlates with post-operative seizures in supratentorial gliomas. J Neurooncol 129, 259–267 (2016). https://doi.org/10.1007/s11060-016-2169-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-016-2169-y